Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 49 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Pipeline Review, H2 2016', provides in depth analysis on Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted pipeline therapeutics. 

The report provides comprehensive information on the Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) 
- The report reviews Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) Overview 6
Therapeutics Development 7
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Products under Development by Stage of Development 7
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Products under Development by Therapy Area 8
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Products under Development by Indication 9
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Pipeline Products Glance 11
Early Stage Products 11
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Products under Development by Companies 12
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Products under Development by Universities/Institutes 14
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Companies Involved in Therapeutics Development 22
Momenta Pharmaceuticals, Inc. 22
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Drug Profiles 23
Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
CM-30119 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
Drugs to Inhibit Heparanase for Oncology - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
necuparanib - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
Polysaccharides to Inhibit Heparanase for Oncology - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
roneparstat - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Small Molecule to Inhibit Heparanase for Lung Cancer and Pancreatic Cancer - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Small Molecules to Inhibit Heparanase for Metastatic Cancer and Diabetic Nephropathy - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Synthetic Peptide to Inhibit HPSE and VEGF for Oncology - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Dormant Projects 34
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Discontinued Products 36
Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Featured News & Press Releases 37
Aug 04, 2016: Momenta Discontinues Further Accrual of its Phase 2 Trial of Necuparanib in Patients with Pancreatic Cancer Following Planned Interim Futility Analysis 37
Jun 04, 2016: Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at ASCO 37
May 19, 2016: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting 38
Dec 21, 2015: Momenta Resumes Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study 39
Nov 13, 2015: Momenta Announces Temporary Pause of Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study 39
Jun 01, 2015: Momenta Pharmaceuticals to Present New Data From Phase 1 Trial of Necuparanib in Patients With Pancreatic Cancer 39
May 18, 2015: Momenta Pharmaceuticals Announces Data Presentation on Necuparanib (M402) at the 2015 ASCO Annual Meeting 40
Dec 01, 2014: Momenta Pharmaceuticals' Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Patients With Metastatic Pancreatic Cancer 41
Oct 09, 2014: Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial of Necuparanib in Patients With Pancreatic Cancer 41
Oct 09, 2014: Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial of Necuparanib in Patients With Pancreatic Cancer 42
Jun 05, 2014: Momenta Pharmaceuticals Receives Orphan Drug Designation for Necuparanib (Formerly M402) in Pancreatic Cancer 43
May 13, 2013: Sigma-Tau announces Phase I study with new anti-cancer heparanase inhibitor SST0001 43
Jul 02, 2012: Momenta Pharma Doses First Patient With M402 In Phase I/II Clinical Trial In Metastatic Pancreatic Cancer 44
Jun 04, 2012: Momenta Pharma Presents Positive Preclinical Results Of M402 In Combination With Gemcitabine At ASCO 2012 Annual Meeting 45
Jun 20, 2011: Momenta Announces Publication Of Preclinical Results Of Oncology Drug M402 In PLoS One 46
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49

List of Tables

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Stage and Mechanism of Action, H2 2016 17
Number of Products by Stage and Route of Administration, H2 2016 19
Number of Products by Stage and Molecule Type, H2 2016 21
Pipeline by Momenta Pharmaceuticals, Inc., H2 2016 22
Dormant Projects, H2 2016 34
Dormant Projects (Contd..1), H2 2016 35
Discontinued Products, H2 2016 36